Diabetes in the United States today is an explosive major public health issue that directly impacts cardiovascular morbidity and mortality. One major reason for these devastating cardiovascular complications is that diabetics exhibit impaired collateral vessel development. Formation of functional collateral blood vessels is the primary adaptive mechanism in humans to blood flow obstruction. In this project we will explore the role of advanced glycation end products and the specific receptor for advanced glycation end products (RAGE) in inhibition of collateral blood vessel formation. We have developed exciting preliminary data showing that advanced glycation end products dramatically inhibit collateral vessel formation. Moreover, we have presented preliminary data that demonstrate a central role for RAGE signaling in monocytes in this process. The proposed studies will first examine the overall role of RAGE in inhibiting collateral vessel formation. Subsequent aims will study the specific contributions of RAGE in monocytes and T cells as these two inflammatory cells types have been shown by us and others to be critical for the formation of collateral blood vessels. Additional studies will examine the role of reactive oxygen species as crucial signaling intermediates in RAGE signal transduction in both monocytes and T cells. Through these studies, we will develop a comprehensive and critical assessment of the role of RAGE signaling in inflammatory cells and the subsequent impact on collateral vessel formation.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL095070-04
Application #
8380232
Study Section
Special Emphasis Panel (ZHL1-PPG-A)
Project Start
Project End
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
4
Fiscal Year
2012
Total Cost
$383,513
Indirect Cost
$117,274
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Heath, Jack M; Fernandez Esmerats, Joan; Khambouneheuang, Lucky et al. (2018) Mechanosensitive microRNA-181b Regulates Aortic Valve Endothelial Matrix Degradation by Targeting TIMP3. Cardiovasc Eng Technol 9:141-150
Forrester, Steven J; Kikuchi, Daniel S; Hernandes, Marina S et al. (2018) Reactive Oxygen Species in Metabolic and Inflammatory Signaling. Circ Res 122:877-902
Paredes, Felipe; Sheldon, Kely; Lassègue, Bernard et al. (2018) Poldip2 is an oxygen-sensitive protein that controls PDH and ?KGDH lipoylation and activation to support metabolic adaptation in hypoxia and cancer. Proc Natl Acad Sci U S A 115:1789-1794
Xu, Qian; Kulkarni, Amol A; Sajith, Ayyiliath M et al. (2018) Design, synthesis, and biological evaluation of inhibitors of the NADPH oxidase, Nox4. Bioorg Med Chem 26:989-998
Paredes, Felipe; Suster, Izabela; Martin, Alejandra San (2018) Poldip2 takes a central role in metabolic reprograming. Oncoscience 5:130-131
Lee, Grace Sanghee; Salazar, Hector F; Joseph, Giji et al. (2018) Osteopontin isoforms differentially promote arteriogenesis in response to ischemia via macrophage accumulation and survival. Lab Invest :
Simmons, Craig A; Jo, Hanjoong (2018) Editorial: Special Issue on Heart Valve Mechanobiology : New Insights into Mechanical Regulation of Valve Disease and Regeneration. Cardiovasc Eng Technol 9:121-125
Williams, Holly C; Ma, Jing; Weiss, Daiana et al. (2018) The cofilin phosphatase slingshot homolog 1 restrains angiotensin II-induced vascular hypertrophy and fibrosis in vivo. Lab Invest :
Yeligar, Samantha M; Kang, Bum-Yong; Bijli, Kaiser M et al. (2018) PPAR? Regulates Mitochondrial Structure and Function and Human Pulmonary Artery Smooth Muscle Cell Proliferation. Am J Respir Cell Mol Biol 58:648-657
Vukelic, Sasa; Xu, Qian; Seidel-Rogol, Bonnie et al. (2018) NOX4 (NADPH Oxidase 4) and Poldip2 (Polymerase ?-Interacting Protein 2) Induce Filamentous Actin Oxidation and Promote Its Interaction With Vinculin During Integrin-Mediated Cell Adhesion. Arterioscler Thromb Vasc Biol 38:2423-2434

Showing the most recent 10 out of 125 publications